Stay updated with breaking news from Argot Partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ReNAgade Therapeutics a company unlocking the limitless potential for RNA medicines today announced its ongoing commitment to unlock the potential of glycobiology through support for ongoing research at GanNA Bio and an integration of the key founders of GanNA Bio into the ReNAgade ecosystem.
ReNAgade Therapeutics a company unlocking the limitless potential for RNA medicines today announced an oral and poster presentation highlighting preclinical data supporting its comprehensive RNA technology platform at the American Society of Gene Cell Therapy ASGCT 27th Annual Meeting being held May 711 2024 in Baltimore Maryland.
FDA Approval Provides for Room Temperature (25°C) Storage Conditions for up to 4 Weeks at Any Point During the 36-Month Approved Shelf LifeExtends...
4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITD...
28.02.2024 - 4Q 2023 Total Revenue of $73.9 Million; FY 2023 Total Revenue of $258.2 Million 4Q 2023 Adjusted EBITDA(1) of $18.6 Million; FY 2023 Adjusted EBITDA of $40.3 Million 4Q 2023 Adjusted Net Income(2) of $8.5 Million; FY 2023 Adjusted Net ...